Aldeyra Therapeutics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for ALDX, updated each market day.
ALDX AI Sentiment
AI sees no strong directional signal for Aldeyra Therapeutics, Inc. stock over the next 10 market days.
Prediction date: Sept. 21, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Sector
Exchange
Market Cap
$83,250,460
Cap Tier
Employees
6
Headquarters
LEXINGTON, MA
Listed Since
May 2, 2014
Website
ALDX Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ALDX Volatility
Aldeyra Therapeutics, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
